Showing 4801-4810 of 9927 results for "".
- COVID-19, the Stock Market, and Dermatologyhttps://practicaldermatology.com/news/covid-19-the-stock-market-and-dermatology/2460688/By Amylee Martin, BS, Akshitha Thatiparthi, BS, Jeffrey Liu, BS, Jashin J. Wu, MD Novel coronavirus, COVID-19, is not only a major public health threat but has also impacted the economy. Due to the pandemic, experts predict a 0.5% decrease in t
- Cassiopea Submits NDA for New Acne Treatmenthttps://practicaldermatology.com/news/cassiopea-submits-nda-for-new-acne-treatment/2460131/Cassiopea SpA submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for clascoterone cream 1% for the treatment of acne. Clascoterone cream 1% is under investigation as a first-in-class topical androgen receptor inhibitor for th
- Sonrei Sea Clearly Gel Sunscreens Launchhttps://practicaldermatology.com/news/sonrei-sea-clearly-gel-sunscreens-launch/2460070/A new eco-friendly, gel-based sunscreen line from Sonrei, LLC is now available. “Crafted for every kind,” Sonrei is driven by a commitment of bringing to market a translucent broad-spectrum SPF with environmental principles at the core, the company says. Sonrei Sea Clearly T
- ISHRS Awareness Campaign Takes on Black Market Hair Restoration Clinicshttps://practicaldermatology.com/news/ishrs-awareness-campaign-takes-on-black-market-hair-restoration-clinics/2460016/The International Society of Hair Restoration Surgery (ISHRS) is launching a new public awareness campaign to help patients recognize “black market pirate” hair restoration clinics and misleading advertising claims. Social media engagement will be the cornerstone of the new
- Study Highlights Adverse Events Associated with Energy-Based Vaginal Rejuvenationhttps://practicaldermatology.com/news/study-highlights-adverse-events-associated-with-energy-based-vaginal-rejuvenation/2460010/Concerns from the federal Food and Drug Administration (FDA) sired the first assessment of adverse events related to device-based procedures marketed for ‘vaginal rejuvenation,’ and the new analysis of the Manufacturer and User Facility Device Experience (MAUDE) database identified a
- Encore Dermatology Acquires Marketing Rights to Promius Pharma Brandshttps://practicaldermatology.com/news/encore-dermatology-acquires-marketing-rights-to-promius-pharma-brands-1/2459989/Encore Dermatology is purchasing the US rights to market Sernivo® (betamethasone dipropionate) Spray, 0.05% and is being assigned the rights to market and distribute Promiseb® Topical Cream and Trianex® 0.05% (Triamcinolone Acetonide Ointment, USP) from Dr. Reddy’
- Constellation Alpha Capital Corp. Signs Letter of Intent to Acquire DermTech, Inc.https://practicaldermatology.com/news/constellation-alpha-capital-corp-signs-letter-of-intent-to-acquire-dermtech-inc/2459970/Constellation Alpha Capital Corp., a special purpose acquisition company, has executed a non-binding Letter of Intent to merge with DermTech, Inc., a molecular genomics company with an initial focus on skin cancer. DermTech markets and develops products that facilitate the early detection of skin
- Patricia Altavilla Named New CEO at Suneva Medicalhttps://practicaldermatology.com/news/patricia-altavilla-named-new-ceo-at-suneva-medical/2459982/Patricia Altavilla is the new Chief Executive Officer of Suneva® Medical, Inc. An industry vet, Altavilla began her career at Mentor Corporation, serving as Vice President of International Sales and Worldwide Marketing. For n
- FDA Clears Sculptura Radiation Oncology System from Sensus Healthcarehttps://practicaldermatology.com/news/fda-clears-sculptura-radiation-oncology-system-from-sensus-healthcare/2459884/The FDA has granted market clearance for the Sculptura radiation oncology system from Sensus Healthcare, Inc. With a single treatment during surgery, Sculptura can provide cancer patients and physicians a single radiation treatment at the
- Dermatology Drugs Market to Reach $34.5 Billion by 2023https://practicaldermatology.com/news/dermatology-drugs-market-to-reach-345-billion-by-2023/2459895/The dermatology drugs market is expected to reach $34.5 billion by 2023, a new report suggests. Research and Markets says that, among